The treatment of chronic myeloid leukemia (CML) has substantially evolved since the FDA approval of the tyrosine kinase inhibitor imatinib in 2001 - the first targeted therapy for CML. Since then, several second- and third- generation TKIs have emerged in the field, as well as other novel therapies. Despite this, around 20-30% of patients with CML will require changes of treatment due to resistance, intolerance or suboptimal responses and thus alternative treatment approaches are needed.
In this podcast, Joaquin Martinez-Lopez, MD, PhD, of the Universidad Complutense de Madrid, Madrid, Spain, gives a brief overview of unmet needs and novel therapeutic approaches for patients with CML, as discussed at the 18th International Myeloma Workshop (IMW 2021).
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
Updates, challenges and novel agents being explored in BPDCN
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
iwNHL 2023 Session V: Expanding the CAR platform in NHL
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.